Most people think of Social Security as a program that helps retirees pay their bills, but there is another important aspect to it; disability income. The SSA pays out benefits to those who have earned enough to be eligible for Social Security but are not yet old enough to claim it, when they can't work for a year or more due to a physical or mental condition.
Silencing of HIF-1α suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis
Hypoxia-inducible factor-1α (HIF-1α) is a main responder to intracellular hypoxia and is overexpressed in many human cancers, including renal cell carcinoma (RCC).
GlaxoSmithKline introduces CARES by GSK to improve patient access to GSK oncology and specialty medicines
Renal Cell Carcinoma: Similar Survival Between Combination And Single Therapy, But Longer Remissions In Some Patients
An article published Online First and in an upcoming edition of The Lancet reports that combination therapy for renal cell carcinoma does not improve overall or progression-free survival compared with single therapy using interferon alfa-2a alone.
To determine whether there has been a change in typical symptoms of renal cell carcinoma (RCC), by evaluating the symptoms of patients diagnosed during four decades, as although the increasing incidence of a diagnosis of incidental RCC has been widely reported, the change in other symptoms has not.
Low serum sodium has recently been associated with poor survival in localised renal cell carcinoma (RCC). We now show the prognostic effect of serum sodium in patients with metastatic RCC (mRCC).
Laparoscopic renal cryoablation is effective oncological treatment for a renal mass in select patients. A disease specific survival rate of 92 percent at 5 years and 83 percent at 10 years is possible.
Neoadjuvant targeted therapy can be used in patients with unresectable locally advanced, locally recurrent or metastatic renal cell carcinoma to induce cytoreduction before surgical resection.
A 42-year-old white man with no significant prior medical history presented with macroscopic hematuria of 2 months' duration. His family history was notable for a maternal grandfather with kidney cancer.
The drug candidate ANYARA, using the TTS technology, is currently in pivotal Phase III clinical trials for Renal Cell Cancer. The primary endpoint is overall survival and results from these studies are expected first half of 2011.
|NeonCRM by Neon One|